May 17, 2012

You are here: Home / biotech / Teva (TEVA) confident that process towards biogenerics momentum will grow

Teva (TEVA) confident that process towards biogenerics momentum will grow

November 15, 2007 By Zack Miller 2 Comments

I stumbled across the Reuters Health Summit that’s taking place in New York this week. Interestingly enough, they’re blogging the conference, so cheap investors like me can “attend” remotely. You can find the blog for the summit here.

Israeli generics giant, Teva Pharmaceuticals (Nasdaq: TEVA), participated and there’s a great (short) audio clip on what Teva believes in happening in the biogenerics space during and after the election cycle. Go here to check it out.

Filed Under: biotech, israel, pharma, Teva Tagged With: , , , , ,
About Zack Miller

Zack Miller is the Managing Director of Israel Newsletter, Lighthouse Capital and the author of acclaimed, Tradestream your Way to Profits: Building a Killer Portfolio in the Age of Social Media (Wiley, 2010).

Trackbacks

  1. EPIX Pharmaceuticals(EPIX): Hey Ma Look What I Found | Israel Opportunity Investor says:
    December 21, 2007 at 12:48 pm

    [...] is huge. Consider as well, with an aging population this could be absolutely huge for the little Biotech company with a market-cap of just $141 million. After seeing the stock surge more than 50% on the [...]

  2. TEVA's Parkinson's Breakthrough | Israel Opportunity Investor says:
    June 17, 2008 at 9:52 am

    [...] Teva, this drug has the potential to generate $1billion is sales, and be a mega-drug. Teva, biggest generic drug company in the world, has also turned into a R&D powerhouse focusing on [...]

Speak Your Mind

*